CELC - Celcuity Inc.

QQQ $ 611.61 $ -5.98 (-0.97 %)

DIA $ 479.35 $ -2.07 (-0.43 %)

SPY $ 675.97 $ -4.53 (-0.67 %)

TLT $ 89.77 $ -0.03 (-0.03 %)

GLD $ 386.93 $ -0.35 (-0.09 %)

Previous Close

$ 85.15

Open

$ 82.99

Bid

$ 85.44 x 61

Ask

$ 86.62 x 277

Day's Range

$ 82.28 - $ 87.16

52 Week Range

$ 7.58 - $ 85.23

Volume

1,329,981

Average Volume

Market Cap

3.61B

Beta (5Y Monthly)

$ 0.61

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-14-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-31-2025	12-31-2024	10-K
4	11-14-2024	09-30-2024	10-Q
5	08-14-2024	06-30-2024	10-Q
6	05-15-2024	03-31-2024	10-Q
7	03-27-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-11-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-23-2023	12-31-2022	10-K
12	11-10-2022	09-30-2022	10-Q
13	08-12-2022	06-30-2022	10-Q
14	05-16-2022	03-31-2022	10-Q
15	03-23-2022	12-31-2021	10-K
16	11-09-2021	09-30-2021	10-Q
17	08-11-2021	06-30-2021	10-Q
18	05-10-2021	03-31-2021	10-Q
19	02-16-2021	12-31-2020	10-K
20	11-09-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-13-2020	12-31-2019	10-K
24	11-07-2019	09-30-2019	10-Q
25	08-08-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	03-01-2019	12-31-2018	10-K
28	11-13-2018	09-30-2018	10-Q
29	08-09-2018	06-30-2018	10-Q
30	05-14-2018	03-31-2018	10-Q
31	03-15-2018	12-31-2017	10-K
32	11-13-2017	09-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Stifel Maintains Buy on Celcuity, Raises P...
11/13/2025 16:00:31

Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $68 to $115.

Celcuity Q3 Adj. EPS $(0.78) Beats $(1.01)...
11/12/2025 21:02:26

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.01) by 2...

Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

Exploring Celcuity's Earnings Expectations
11/11/2025 14:03:35

HC Wainwright & Co. Maintains Buy on Celcu...
10/22/2025 11:49:48

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

ww-international-replimune-group-datavault-ai-grail-and-other-big-stocks-moving-higher-on-monday

WW International, Replimune Group, Datavau...
10/20/2025 14:13:22

dow-jumps-over-200-points-cleveland-cliffs-shares-jump-after-q3-results

Dow Jumps Over 200 Points; Cleveland-Cliff...
10/20/2025 13:49:54

12 Health Care Stocks Moving In Monday's P...
10/20/2025 12:08:17

Needham Reiterates Buy on Celcuity, Mainta...
10/20/2025 10:10:53

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket

Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

Reported Saturday, Celcuity Presented Phas...
10/20/2025 08:18:12

Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67%No patients di...

Reported Saturday, Celcuity Announces Phas...
10/20/2025 08:16:32

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of...

Needham Reiterates Buy on Celcuity, Mainta...
10/03/2025 10:38:42

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

Celcuity To Present Phase 3 VIKTORIA-1 Bre...
09/22/2025 13:17:34

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

Guggenheim Initiates Coverage On Celcuity ...
09/22/2025 10:57:45

Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of ...

Celcuity's NDA For Gedatolisib In HR+/HER2...
08/27/2025 20:14:22

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

HC Wainwright & Co. Maintains Buy on Celcu...
08/18/2025 10:34:59

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

Needham Maintains Buy on Celcuity, Lowers ...
08/15/2025 10:05:13

Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.

Celcuity Q2 Adj. EPS $(0.93) Misses $(0.88...
08/14/2025 20:03:43

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.88) by...